Industry, Innovation and Science
To operate facilities constructed as part of the ANSTO Nuclear Medicine project, including: - an export scale nuclear medicine manufacturing plant which will secure Australia's ability to produce one of the world's most important nuclear medicines, Molybdenum-99 (Mo-99); and, - a collocated Synroc waste treatment plant which will deliver a permanent, safe and economical way of treating the necessary by-products from past, current and future manufacture of nuclear medicines. The subsidiary will also participate and invest in nuclear medicine and related activities, including applied research and development aligned and complementary to its core facilities and competencies.

Further information

  • Type of Body

    I. Subsidiaries of Corporate Commonwealth Entities and Commonwealth Companies

  • Established By / Under

    Corporations Act 2001 / Company / Trust Deed / Partnership

  • Paid Members?

    Yes

  • Max No. of Board/Committee Members

    5

  • Annual Report Prepared and tabled?

    No

  • Classification

    C. Other

  • Auditor

    ANAO

  • Creation Date

    10 September 2013

Last updated: